Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Veru Inc. (NASDAQ: VERU) has been added to the Russell 2000® and Russell 3000® Indices, effective today, following Russell's annual reconstitution. This inclusion is expected to enhance visibility and attract investment. The Russell 2000 Index includes small-cap stocks representing about 10% of the total market cap of the Russell 3000 Index, which covers approximately 98% of the U.S. equity market. Veru focuses on developing treatments for prostate cancer, with several products in clinical trials and a growing portfolio in urology.
Veru Inc. (NASDAQ: VERU) has commenced its Phase 2 clinical trial for VERU-111, a microtubule depolymerization drug aimed at treating COVID-19. The trial will enroll 40 hospitalized patients at high risk for acute respiratory distress syndrome (ARDS). Patients will receive either VERU-111 or a placebo for 21 days. The drug has shown potential for inhibiting SARS-CoV-2 and alleviating severe inflammation related to the virus. The primary endpoint is the proportion of patients alive without respiratory distress by Day 29. Quick enrollment is anticipated due to rising COVID-19 cases.
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on oncology and urology, will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 9:30 a.m. ET. The presentation will cover the company's prostate cancer treatments, including VERU-111, which is currently in clinical trials for metastatic castration-resistant prostate cancer. Other pipeline products include Zuclomiphene citrate and VERU-100, targeting advanced prostate cancer. A webcast of the presentation will be available on their website for at least 90 days post-event.
Veru Inc. (NASDAQ: VERU) reported a significant 43% increase in net revenues, reaching $9.9 million for Q2 FY 2020, and a 61% rise in gross profit to $7.4 million. The gross margin improved to 75%. The company is progressing in its clinical trials, with positive Phase 1b results for VERU-111 in treating advanced prostate cancer and FDA clearance for a Phase 2 COVID-19 study. Operating loss narrowed to $0.3 million compared to $2.1 million last year. The results highlight strong growth in prescription sales and bolster Veru's position in oncology therapeutics.
Veru Inc. (NASDAQ: VERU) has received FDA approval to initiate a Phase 2 clinical trial for VERU-111, an oral microtubule depolymerization agent, targeting COVID-19 treatment. This trial will assess its efficacy in hospitalized patients at high risk for acute respiratory distress syndrome (ARDS). The trial will involve 40 subjects, comparing VERU-111 to a placebo over 21 days. Following its promising Phase 1b results in prostate cancer, this dual-action agent aims to combat both the virus and inflammatory responses associated with COVID-19.
Veru Inc. announced promising results from the Phase 1b segment of the VERU-111 clinical trial for treating men with metastatic castration-resistant prostate cancer. The study, which included 39 subjects, verified the drug's safety at doses ≤63 mg, with no significant neutropenia or neurotoxicity. Notably, 75% of patients showed PSA declines, and the median duration of response was 10 months. The company plans to collaborate with the FDA next quarter to design a Phase 3 trial, aiming to position VERU-111 as a front-line treatment before chemotherapy.